All In Biotech

Drug Trial Radar · NCT07828210

NeuroAiD Patient-Reported Outcomes in Patients With Mild to Moderate Ischemic Stroke

A Randomized, Controlled Study Evaluating the Efficacy and Safety of MLC901 (NeuroAiD™ II) in Patients With Mild to Moderate Ischemic Stroke.

Last checked: Nov 19, 2026Latest source record: Oct 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

80

Planned (sponsor's estimate)

Start

Sep 10, 2026

Primary completion

Sep 2027

Study completion Dec 2027

Sponsor

Sponsor type
Industry
First posted
Sep 18, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a randomized, controlled, open-label study of MLC901 (NeuroAiD™ II) in patients with mild to moderate ischemic stroke. Eligible participants will be randomized in a 1:1 ratio to receive MLC901 in combination with standard treatment or standard treatment alone for 12 weeks.

Conditions

  • Stroke
  • Stroke, Acute Ischemic
  • Stroke, Ischemic
  • Stroke, Cryptogenic
  • Stroke, Cardiovascular

Interventions

  • MLC901Drug

    MLC901 (NeuroAiD™ II) 400 mg hard capsules, administered orally at a dose of 2 capsules three times daily for 12 weeks, in combination with standard treatment according to the protocol.

  • Standard treatment for acute ischemic strokeOther

    Participants will receive standard treatment for acute ischemic stroke according to the study protocol for 12 weeks

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. EuroQol 5-Dimension 5-Level (EQ-5D-5L)Time frame: Baseline, Day 7 and Day 14
  2. EuroQol Visual Analogue Scale (EQ-VAS)Time frame: Baseline, Day 7 and Day 14
  3. Treatment Satisfaction Questionnaire for Medication Version 1.4 (TSQM-1.4)Time frame: Baseline, Day 7 and Day 14
  4. Adverse EventsTime frame: From baseline through Week 12, and at the optional Week 24 follow-up visit.
  5. Hemorrhagic ComplicationsTime frame: From baseline through Week 12, and at the optional Week 24 follow-up visit.

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Traditional Medicine Institute

    Ho Chi Minh City, Vietnam · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.